SAN FRANCISCO (GenomeWeb News) – Danaher will likely use at least part of its $8 billion available for acquisitions in order to expand its life science and diagnostics portfolio, company President and CEO Larry Culp said at the 32nd Annual JP Morgan Healthcare Conference here this morning.

During the firm’s analyst day meeting last month, Culp said that the firm had at its disposal about $8 billion available to pursue merger and acquisitions and today he reiterated that figure while adding that the firm “will continue to be an active acquirer” throughout 2014 and beyond.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.